Investigational Drug Information for AZD3293
✉ Email this page to a colleague
What is the drug development status for AZD3293?
AZD3293 is an investigational drug.
There have been 15 clinical trials for AZD3293.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 15th 2017.
The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Eli Lilly and Company, and Parexel.
There are fourteen US patents protecting this investigational drug and one hundred and eighty-one international patents.
Summary for AZD3293
| US Patents | 14 |
| International Patents | 181 |
| US Patent Applications | 43 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2017-03-15) |
| Vendors | 30 |
Recent Clinical Trials for AZD3293
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia | AstraZeneca | Phase 3 |
| A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia | Eli Lilly and Company | Phase 3 |
| A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin | AstraZeneca | Phase 1 |
Clinical Trial Summary for AZD3293
Top disease conditions for AZD3293
Top clinical trial sponsors for AZD3293
US Patents for AZD3293
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD3293 | See Plans and Pricing | Compounds, compositions and methods | Denali Therapeutics Inc. (South San Francisco, CA) | See Plans and Pricing |
| AZD3293 | See Plans and Pricing | Compositions and methods for treating HIV-associated neurocognitive disorders | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL) | See Plans and Pricing |
| AZD3293 | See Plans and Pricing | Compounds and their use as BACE inhibitors | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD3293 | See Plans and Pricing | Camsylate salt | ASTRAZENECA AB (Sodertalje, SE) | See Plans and Pricing |
| AZD3293 | See Plans and Pricing | Compounds, compositions and methods | Denali Therapeutics Inc. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD3293
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD3293 | Argentina | AR107537 | 2036-02-05 | See Plans and Pricing |
| AZD3293 | Argentina | AR115780 | 2036-02-05 | See Plans and Pricing |
| AZD3293 | Australia | AU2017213628 | 2036-02-05 | See Plans and Pricing |
| AZD3293 | Brazil | BR112018015410 | 2036-02-05 | See Plans and Pricing |
| AZD3293 | Canada | CA3012832 | 2036-02-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
